To revolutionise the treatment of cerebrovascular and neurodegenerative diseases where there is no effective drug therapy available today.
Diseases of cerebrovascular origins such as resistant hypertension, stroke, Alzheimer’s disease and vascular dementia rank alongside cancer as one of the greatest healthcare challenges faced by humanity, affecting one in three in later life.
Currently, there are no efficient drugs or treatment proven to modify the course of these diseases. Bioinduction has developed a precisely targetted brain pacemaker that offers new hope for the millions of sufferers.
As Wired Health reports: “the future of medication isn’t drugs and their countless side effects but electrical implants!”
1
billion
people across the
world have hypertension
140
million
are not managed
by drugs
7.5
million
die annually worldwide from heart disease and stroke caused by high blood pressure
The Solution
New brain targets identified
Cerebrovascular diseases have one thing in common: a reduction in the cerebral blood flow.
Bioinduction has developed and patented a new treatment that restores normal blood flow to the brain.
Skull-mounted brain pacemaker
To give millions of people access to this treatment, we have developed Picostim, a miniaturised brain pacemaker, which is small enough to be skull-mounted.
Picostim is a third of the size of current devices and can be implanted in half the time.
potential to improve live of millions of people
Team
We have a strong and experienced team to deliver our mission. We all have experience in medical device design and clinical investigations and are continually building our expert team to accelerate our product development and continue to develop the clinical evidence.
Ivor Gillbe
Co-Founder
Inventor of key device technology.
Two previous technology exits.
Nik Patel
Co-Founder
Senior Functional Neurosurgeon.
Inventor of new treatments for cerebrovascular conditions.
Jon Ottaway
Technical architect of Picostim system
15 years’ experience in medical devices software and hardware development.
John Spensley
SARS programme lead (Finetech Medical)
13 years in manufacture and sales of implantable medical devices.
Anton Jenkins
Non-exec
Investor and strategic advisor.
Co-founder of Clinigen Group Plc.
Work with us
Get in touch today to discuss our current career opportunities: